Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.That won't be a problem with Johnson & Johnson (JNJ 0.39%) and Medtronic (MDT -0.53%). They're healthy companies that should continue to pay durable dividends in the decades ahead, making them great income investments. As healthy as it getsJohnson & Johnson is among the world's healthiest companies. The healthcare gia ...

文章核心观点 - 强生公司（Johnson & Johnson, JNJ）已向美国食品药品监督管理局（FDA）提交监管文件，寻求批准其重磅免疫学药物Tremfya（guselkumab）用于溃疡性结肠炎（UC）的皮下（SC）诱导治疗方案 [1][2] 公司动态 - 强生公司计划为UC患者提供更便捷的Tremfya治疗方案，相比静脉注射（IV）剂量，皮下剂量更易管理且更舒适 [3] - 如果此次监管申请获批，Tremfya将成为首个在UC适应症中提供IV或SC诱导治疗选择的IL-23抑制剂 [3] - 此次申请基于III期ASTRO研究的数据，该研究在第12周达到了临床缓解的主要终点，并实现了所有次要终点 [4] - Tremfya已在多个国家（包括美国和欧洲）获批用于银屑病和活动性银屑病关节炎（PsA）适应症 [5] - 强生公司还于6月提交了Tremfya用于中度至重度活动性克罗恩病（CD）的标签扩展申请 [6] - Tremfya是强生免疫学药物组合中的重要药物，2024年前九个月销售额达到27亿美元，同比增长22%，预计将成为50亿美元的产品 [9] 行业背景 - 溃疡性结肠炎（UC）和克罗恩病（CD）是两种主要的炎症性肠病（IBD），近年来由于遗传因素、环境因素和生活方式的改变，其患病率有所上升 [6][7] - 免疫系统异常、更高的诊断率、早期诊断的重视以及发达国家的有利报销政策推动了IBD治疗的需求 [7] - IBD市场竞争激烈，主要参与者包括艾伯维（AbbVie, ABBV）和礼来（Eli Lilly, LLY） [10][11] - 艾伯维的免疫学产品Skyrizi和Rinvoq表现出色，支持了其未来几年的收入增长 [10] - 礼来公司去年获得了FDA对Omvoh用于UC适应症的批准，并正在寻求其用于CD适应症的标签扩展 [11]

Whether you prefer growth stocks, value stocks, dividend stocks, or a mixture of investments in your portfolio, price should only be one factor you consider when determining which businesses to add.Dividends can be a great way to increase your returns with time while giving you extra capital to reinvest or keep in your portfolio. These kinds of stocks can be found across many different sectors and industries.If you're looking for two top dividend stocks to consider for your portfolio and have $500 available ...

Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with our quality scores, buy targets, and trim targets.When it comes to Dividend Elite’s, at the top of the hierarchy are Dividend Kings. Dividend Kings are defined as companies that have increased their dividend for 50+ consecutive years.Brad, along with HOYA Capital, lead the investing group iREIT®+HOYA Cap ...

POLAND - 2024/11/17: In this photo illustration, the AbbVie company logo is seen displayed on a ... [+] smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expected earnings. However, we think that the new drugs that are gaining market ...

J&J (JNJ) stock has plunged 6.1% in a month, losing almost $24 billion of its market value.Though slowing sales in its MedTech segment, the upcoming patent expiration of its blockbuster drug, Stelara, and talc-related legal issues are hurting J&J, a lot of this stock price decline could be due to the broader drug/biotech sector decline in the past month. Lower-than-expected sales of Lilly (LLY) and Novo Nordisk’s (NVO) popular diabetes and obesity drugs in the third quarter, guidance cuts, pipeline setbacks ...

行业核心观点 - 医疗保健行业通常在经济动荡时期以稳定性著称但如今并非如此因为有罗伯特·F·肯尼迪（Robert F. Kennedy, Jr.）将被任命为部门负责人的推测导致未来政策存在不确定性[1]

公司核心观点 - 强生公司将在第66届美国血液学会(ASH)年会上展示超过90份摘要，涵盖其血液癌症产品组合和管线的临床试验及真实世界数据，强调公司在血液恶性肿瘤治疗领域的领导地位和创新承诺[1] 公司产品组合与创新 - 公司展示了在多发性骨髓瘤治疗各阶段的进展，包括差异化和有前景的联合治疗方案，如DARZALEX FASPRO®的多种组合疗法[2] - 在B细胞恶性肿瘤治疗方面，公司通过IMBRUVICA®的固定持续时间组合展示了长期益处，特别是在慢性淋巴细胞白血病中的应用[2] - 公司在急性髓性白血病(AML)领域通过menin抑制剂bleximenib的1期项目展示了应对未满足需求的承诺[3] 罕见疾病研究 - 公司研究了温自身免疫性溶血性贫血(wAIHA)和胎儿及新生儿同种免疫性血小板减少症(FNAIT)等罕见疾病的患者体验和健康资源利用情况，强调了这些疾病的治疗需求和研究进展[3][4] 产品介绍 - DARZALEX FASPRO®和DARZALEX®是公司针对多发性骨髓瘤的CD38定向抗体，分别于2020年和2015年获得FDA批准，广泛应用于多发性骨髓瘤的治疗[9][10] - CARVYKTI®是一种BCMA定向的CAR-T细胞疗法，于2022年获得FDA批准，用于治疗复发或难治性多发性骨髓瘤患者[14][15] - TECVAYLI®是一种双特异性T细胞接合抗体，于2022年获得FDA批准，用于治疗复发或难治性多发性骨髓瘤患者[19] - TALVEY®是一种GPRC5D定向的双特异性抗体，于2023年获得FDA批准，用于治疗复发或难治性多发性骨髓瘤患者[21] - IMBRUVICA®是一种每日一次的口服药物，用于治疗多种血液癌症，已在全球范围内广泛使用[22] - Nipocalimab是一种研究性单克隆抗体，旨在通过阻断FcRn来减少循环免疫球蛋白G(IgG)抗体，应用于多种自身抗体相关疾病[24] 行业背景 - 多发性骨髓瘤是一种不可治愈的血液癌症，2024年美国预计有超过35,000人被诊断，超过12,000人将死于该疾病，5年生存率为59.8%[5] - 冒烟型多发性骨髓瘤(SMM)是多发性骨髓瘤的前驱状态，15%的新诊断多发性骨髓瘤病例为SMM，其中一半的高风险患者将在两年内进展为活动性多发性骨髓瘤[6] - 温自身免疫性溶血性贫血(wAIHA)是一种罕见的危及生命的疾病，每年每100,000人中有1-3例新发病例，目前没有FDA批准的药物[7] - 胎儿及新生儿同种免疫性血小板减少症(FNAIT)是一种罕见的同种免疫性疾病，影响1/1000的妊娠，可能导致严重的出血并发症[8]

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24Comprehensive results are being prepared for presentation at upcoming medical congressesSPRING HOUSE, Pa., Nov. 18, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal ...

公司参会人员相关 - 公司参会人员有Michael Bodner（集团总裁，心脏恢复和循环修复部门）以及来自投资者关系部门的Alec Mast和Tracy Menkowski [1] 公司业务相关 - Michael Bodner领导Abiomed和Shockwave特许经营业务，这两项业务目前约占强生公司总销售额的3.5%，分别于2022年12月和2024年5月被收购 [1][2] - Michael Bodner是一位经验丰富的介入心脏病学高管，有15年以上经验，之前是强生全球领先的Biosense Webster、EP业务的全球总裁 [2] 会议相关 - 这是在2024年11月18日上午10:55举行的Stifel 2024医疗保健会议，强生公司参加了此次会议 [1] 问答环节相关 - 强生花费300亿美元将Shockwave和Abiomed纳入旗下，在TCT（经导管心血管治疗学术会议）上，强生在临床会议中有很大的影响力，Rick Wise想知道Michael Bodner的印象 [4]